Effect of Protocolized Magnesium Replacement on Mortality and Atrial Fibrillation in Critically Ill Patients

Study acronym: MAGNOLIA
StatusRecruiting
PhasePhase 4
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment increased: 3253 → 3853 participants
    • Eligibility criteria expanded, about 7 words
    • Secondary endpoints: details revised at 3 of 18 entries
    • Study description revised
  2. Study sites: 5 to 6v5
  3. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised at 5 of 5 sites
    v4
  4. Start date: Nov 1, 2025 to Nov 25, 2025v3
  5. Interventions: Higher target (>0.95mmol/L) (Drug), Lower target (>0.7mmol/L) (Drug) to Magnesium glucoheptonate (Drug), Magnesium oxide (Drug), Magnesium sulfate administration (Drug)
    • Secondary endpoints: 16 to 18
    • Study description shortened, about 3 words
    v2
  6. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
In patients with critical illness, such as severe infections, heart attacks, or respiratory failure, most intensive care units (ICUs) measure magnesium levels and give supplemental doses of magnesium when levels are below certain targets. However, the best targets are unknown. The goal of this clinical trial is to study protocols for magnesium supplementation in people with critical illness, comparing a protocol with higher target level to a protocol with a lower target level. The main question this study aims to answer is whether magnesium supplementation protocols targeting a higher or lower level lead to better 30-day survival and less atrial fibrillation. Participants will not have to do any specific tasks, undergo any additional tests, or complete any surveys.
Trial Details
NCT Number NCT07173855
Lead Sponsor Scarborough General Hospital
Collaborators: Scarborough Health Network, Lakeridge Health Corporation
Conditions
(from sponsor)		 Critical Illness
Related terms Atrial Fibrillation, Critical Illness
Enrollment 3,853 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov